Tyme Technologies, Inc. (TYME) News
Filter TYME News Items
TYME News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TYME News Highlights
- For TYME, its 30 day story count is now at 2.
- Over the past 8 days, the trend for TYME's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about TYME are SYRS.
Latest TYME News From Around the Web
Below are the latest news stories about TYME TECHNOLOGIES INC that investors may wish to consider to help them evaluate TYME as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday and what's moving them! |
Syros and Tyme Technologies Announce Stockholder Approval of Merger-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 20 |
TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and TymeBEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”), today announced that independent proxy advisory firms Glass, Lewis & Co. (“Glass Lewis”) and Institutional Shareholder Services Inc. (“ISS”) have recommended that Tyme stockholders vote “FOR” the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. (“Syros”) and “FOR” all other matters to be voted upon at the Company’s upcoming Special Meeting of Stockholders (the |
Mass. M&A activity picks up among life sciences firmsMergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come. |
Syros to acquire New Jersey biotech Tyme TechnologiesSyros Pharmaceuticals is set to acquire a New Jersey biotech firm called Tyme Technologies Inc., extending its cash runway into 2025 at a time when biotech stocks are being hammered. |
TYME Technologies Shares Surge On Merger Agreement With Syros PharmaSyros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expenses currently estimated to be approximately $60 million. Syros expects to issue approximately 74.3 million shares. TYME stockholders are expected to receive approximately 0.4312 shares of Syros shares for each share of TYME share. The combined company will be led by Syros' existing management team, inc |
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private PlacementCAMBRIDGE, Mass. & BEDMINSTER, N.J., July 05, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-down and transaction expenses is currently estimated to be approximately $60 |
TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results-- $84.0 million in cash and marketable securities as of March 31, 2022 --BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022. In March the Company announced that its Board of Directors decided to explore potential strategic options to enhance |
Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
TYME Technologies Reviews Potential Strategic OptionsTYME Technologies Inc (NASDAQ: TYME) has decided to explore potential strategic options. It has engaged Moelis & Company LLC as its financial advisor and Faegre Drinker Biddle & Reath LLP as its legal advisor. In January, TYME announced the discontinuation of a randomized Phase II/III trial of SM-88 in combination with methoxsalen, phenytoin, and sirolimus (MPS) for metastatic pancreatic cancer upon learning that the trial sponsor terminated the study arm due to futility. The Board's Strategic P |